Stock-Based Compensation and Stock Options	6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation and Stock Options	Stock-Based Compensation and Stock Options The Company accounts for its employee stock options under the fair value method, which requires stock-based compensation to be estimated using the fair value on the date of grant using an option-pricing model. The value of the portion of the award that is expected to vest is recognized on a straight-line basis as expense over the related employees’ requisite service periods in the Company’s condensed consolidated statements of operations. In January 2012, the Company granted certain executives stock options to purchase 100,000 shares of common stock with an exercise price of $28.98, of which 25,000 options became exercisable annually starting January 23, 2013. The options expire in January 2022. During 2014, 25,000 options were canceled and 25,000 options were forfeited upon the departure of an executive. As of June 30, 2018, 50,000 options were outstanding and vested. As of June 30, 2018, there was no unrecognized stock-based compensation expense relating to these options. In September 2015, the Company granted an executive stock options to purchase 400,000 shares of common stock with an exercise price of $8.07, of which 50,000 options became exercisable quarterly starting March 31, 2016. The options expire in September 2025. As of June 30, 2018, 400,000 options were vested and outstanding. As of June 30, 2018, there was no unrecognized stock-based compensation expense relating to these options. In March 2016, the Company granted certain executives stock options to purchase 150,000 shares of common stock with an exercise price of $8.55, of which 37,500 options vest and become exercisable annually starting on March 7, 2017. The options expire in March 2026. In 2017, 37,500 options were forfeited and 12,500 options were canceled upon the departure of an executive and the compensation expense of $19,000 was reversed. As of June 30, 2018, 100,000 options were outstanding and 50,000 of these options were vested. Total stock-based compensation for the three months ended June 30, 2018, related to these option grants was $30,000. As of June 30, 2018, there was approximately $199,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 1.7 years. In October 2017, the Company granted an executive stock options to purchase 400,000 shares of common stock with an exercise price of $6.95, of which 50,000 shares are exercisable quarterly starting March 31, 2018 and ending on December 31, 2019. The options expire in 2027. As of June 30, 2018, 400,000 options were outstanding and 100,000 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $143,000 and $287,000, respectively. As of June 30, 2018, there was approximately $860,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 1.5 years. In April 2018, the Company granted an employee stock options to purchase 50,000 shares of common stock with an exercise price of $10.50. The options vest in twelve equal installments. The first installment vested on April 26, 2018, and the remaining eleven installments vest from June 30, 2018 to December 31, 2020. As of June 30, 2018, $50,000 options were outstanding and 8,333 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $40,000. As of June 30, 2018, there was approximately $201,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 2.5 years. In May 2018, the Company granted an employee options to purchase 50,000 shares of common stock with an exercise price of $14.70, of which 12,500 options will vest and become exercisable annually starting on May 2019. As of June 30, 2018, 50,000 options were outstanding and none of these options was vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $11,000. As of June 30, 2018, there was approximately $347,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 3.9 years. In June 2018, the Company granted a nonemployee consultant options to purchase 100,000 shares of common stock with an exercise price of $17.75, of which 20,000 options vested and became exercisable on June 8, 2018, 30,000 shares will vest no later than July 31, 2018 if certain performance targets are met, and 50,000 shares will vest no later than June 30, 2019 if certain performance targets are met. The Company used the contractual life when determining the value of this option. Based upon the performance conditions, the remaining unvested options will be measured and expensed when and if performance targets are met and vesting occurs. As of June 30, 2018, 100,000 options were outstanding and 20,000 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $122,000. In June 2018, the Company granted an employee options to purchase 50,000 shares of common stock with an exercise price of $16.65, of which 12,500 options will vest and become exercisable annually starting on June 2019. As of June 30, 2018, 50,000 options were outstanding and none of these options was vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $2,000. As of June 30, 2018, there was approximately $403,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 4.0 years.

Stock-Based Compensation and Stock Options

The Company accounts for its employee stock options under the fair value method, which requires stock-based compensation to be estimated using the fair value on the date of grant using an option-pricing model. The value of the portion of the award that is expected to vest is recognized on a straight-line basis as expense over the related employees’ requisite service periods in the Company’s condensed consolidated statements of operations.

In January 2012, the Company granted certain executives stock options to purchase 100,000 shares of common stock with an exercise price of $28.98, of which 25,000 options became exercisable annually starting January 23, 2013. The options expire in January 2022. During 2014, 25,000 options were canceled and 25,000 options were forfeited upon the departure of an executive. As of June 30, 2018, 50,000 options were outstanding and vested. As of June 30, 2018, there was no unrecognized stock-based compensation expense relating to these options.

In September 2015, the Company granted an executive stock options to purchase 400,000 shares of common stock with an exercise price of $8.07, of which 50,000 options became exercisable quarterly starting March 31, 2016. The options expire in September 2025. As of June 30, 2018, 400,000 options were vested and outstanding. As of June 30, 2018, there was no unrecognized stock-based compensation expense relating to these options.

In March 2016, the Company granted certain executives stock options to purchase 150,000 shares of common stock with an exercise price of $8.55, of which 37,500 options vest and become exercisable annually starting on March 7, 2017. The options expire in March 2026. In 2017, 37,500 options were forfeited and 12,500 options were canceled upon the departure of an executive and the compensation expense of $19,000 was reversed. As of June 30, 2018, 100,000 options were outstanding and 50,000 of these options were vested. Total stock-based compensation for the three months ended June 30, 2018, related to these option grants was $30,000. As of June 30, 2018, there was approximately $199,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 1.7 years.

In October 2017, the Company granted an executive stock options to purchase 400,000 shares of common stock with an exercise price of $6.95, of which 50,000 shares are exercisable quarterly starting March 31, 2018 and ending on December 31, 2019. The options expire in 2027. As of June 30, 2018, 400,000 options were outstanding and 100,000 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $143,000 and $287,000, respectively. As of June 30, 2018, there was approximately $860,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 1.5 years.

In April 2018, the Company granted an employee stock options to purchase 50,000 shares of common stock with an exercise price of $10.50. The options vest in twelve equal installments. The first installment vested on April 26, 2018, and the remaining eleven installments vest from June 30, 2018 to December 31, 2020. As of June 30, 2018, $50,000 options were outstanding and 8,333 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $40,000. As of June 30, 2018, there was approximately $201,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 2.5 years.

In May 2018, the Company granted an employee options to purchase 50,000 shares of common stock with an exercise price of $14.70, of which 12,500 options will vest and become exercisable annually starting on May 2019. As of June 30, 2018, 50,000 options were outstanding and none of these options was vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $11,000. As of June 30, 2018, there was approximately $347,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 3.9 years.

In June 2018, the Company granted a nonemployee consultant options to purchase 100,000 shares of common stock with an exercise price of $17.75, of which 20,000 options vested and became exercisable on June 8, 2018, 30,000 shares will vest no later than July 31, 2018 if certain performance targets are met, and 50,000 shares will vest no later than June 30, 2019 if certain performance targets are met. The Company used the contractual life when determining the value of this option. Based upon the performance conditions, the remaining unvested options will be measured and expensed when and if performance targets are met and vesting occurs. As of June 30, 2018, 100,000 options were outstanding and 20,000 of these options were vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $122,000.

In June 2018, the Company granted an employee options to purchase 50,000 shares of common stock with an exercise price of $16.65, of which 12,500 options will vest and become exercisable annually starting on June 2019. As of June 30, 2018, 50,000 options were outstanding and none of these options was vested. Total stock-based compensation for the three and six months ended June 30, 2018, related to these option grants was $2,000. As of June 30, 2018, there was approximately $403,000 of unrecognized stock-based compensation expense relating to these options. This amount is expected to be recognized over 4.0 years.